Commentary

Video

The Role of Biomarker Testing in Metastatic and Resectable NSCLC

Author(s):

Jessica Donington, MD, MSCR,Melina Elpi Marmarelis, MD

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

Related Videos
Ewa Kalinka, MD, PhD
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Dimitrios Nasioudis, MD
Sandip P. Patel, MD
Michael R. Bishop, MD
Related Content
Maurie Markman, MD
January 23rd 2025

Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Limertinib for EGFR T790M+ NSCLC | Image Credit: © catalin – stock.adobe.com
January 17th 2025

Limertinib Wins Approval in China for EGFR T790M+ NSCLC